Pakistan Journal of Pharmaceutical Sciences. 2017; 30 (3 [Special]): 1095-1098
en Inglés
| IMEMR
| ID: emr-189316
ABSTRACT
The purpose of the present research work was to study the CYP2D6 gene polymorphism survival outcome after breast cancer patient received the toremifene and tamoxifen treatment. Seventy-eight patients who received radical mastectomy and toremifene and tamoxifen treatment after operation were divided into three groups CYP2D6*1/*1 group [13 cases], CYP2D6*1/*10 group [28cases] and CYP2D6*10/*10 group [35 cases], according to the gene polymorphism of blood serum CYP2D6. The results of treatment of three groups were compared. After operation the content of blood serum CA125, CA153, VEGF, IGF-1 were all lower than before. The content of CYP2D6*10/*10 group was higher than those of CYP2D6*1/*1 group and CYP2D6*1/*10 group. The content of CYP2D6*1/*1 group had no difference with that of CYP2D6*1/*10 group. All patients were followed up for a median duration of 30.5 months. Progression-free survival [PFS] of CYP2D6*10/*10 was shortened. The recurrence rate increased and the survival rate reduced. There were no obvious differences between CYP2D6*1/*1group and CYP2D6*1/*10 group. In summary, CYP2D6 gene polymorphism relates with the effect of toremifene and tamoxifen treatment in patient with ER positive breast cancer and null allele homozygote CYP2D6*10/*10 can lead to a poor prognosis
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Asunto principal:
Polimorfismo Genético
/
Tamoxifeno
/
Toremifeno
/
Citocromo P-450 CYP2D6
Límite:
Anciano
/
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Pak. J. Pharm. Sci.
Año:
2017
Similares
MEDLINE
...
LILACS
LIS